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METHODOLOGY ARTICLE

Open Access

Non-synonymous variations in cancer and their
effects on the human proteome: workflow for
NGS data biocuration and proteome-wide analysis
of TCGA data
Charles Cole1†, Konstantinos Krampis2†, Konstantinos Karagiannis1, Jonas S Almeida3, William J Faison1,
Mona Motwani1, Quan Wan1, Anton Golikov4, Yang Pan1, Vahan Simonyan4 and Raja Mazumder1,5*

Abstract
Background: Next-generation sequencing (NGS) technologies have resulted in petabytes of scattered data,
decentralized in archives, databases and sometimes in isolated hard-disks which are inaccessible for browsing and
analysis. It is expected that curated secondary databases will help organize some of this Big Data thereby allowing
users better navigate, search and compute on it.
Results: To address the above challenge, we have implemented a NGS biocuration workflow and are analyzing
short read sequences and associated metadata from cancer patients to better understand the human variome.
Curation of variation and other related information from control (normal tissue) and case (tumor) samples will
provide comprehensive background information that can be used in genomic medicine research and application
studies. Our approach includes a CloudBioLinux Virtual Machine which is used upstream of an integrated Highperformance Integrated Virtual Environment (HIVE) that encapsulates Curated Short Read archive (CSR) and a
proteome-wide variation effect analysis tool (SNVDis). As a proof-of-concept, we have curated and analyzed control
and case breast cancer datasets from the NCI cancer genomics program - The Cancer Genome Atlas (TCGA). Our
efforts include reviewing and recording in CSR available clinical information on patients, mapping of the reads to
the reference followed by identification of non-synonymous Single Nucleotide Variations (nsSNVs) and integrating
the data with tools that allow analysis of effect nsSNVs on the human proteome. Furthermore, we have also
developed a novel phylogenetic analysis algorithm that uses SNV positions and can be used to classify the patient
population. The workflow described here lays the foundation for analysis of short read sequence data to identify
rare and novel SNVs that are not present in dbSNP and therefore provides a more comprehensive understanding of
the human variome. Variation results for single genes as well as the entire study are available from the CSR website
(http://hive.biochemistry.gwu.edu/dna.cgi?cmd=csr).
Conclusions: Availability of thousands of sequenced samples from patients provides a rich repository of sequence
information that can be utilized to identify individual level SNVs and their effect on the human proteome beyond
what the dbSNP database provides.
Keywords: SRA, TCGA, nsSNV, SNV, SNP, Next-gen, NGS, Phylogenetics, Cancer
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Background
Researchers in cancer biology are well aware of the possibilities that Big Data can offer and there are already several efforts underway to generate relevant large-scale
cancer genomics data [1-3]. International and national
networks of collaboration, such as International Cancer
Genome Consortium (ICGC) [4], Global Cancer Genomics Consortium (GCGC) [5], Early Detection Research
Network (EDRN) [6] and other NCI programs (like The
Cancer Genome Atlas program (TCGA) [7]), are generating increasingly large amounts of data, the vast majority
of which is from next-generation sequencing (NGS) technologies. TCGA data is expected to surpass 100 petabytes
by the completion of the project. In a recent survey of the
files generated by the TCGA initiative we found that its
file count has been doubling every 7 months since 2010,
with a total count above 700,000 files. Although, it is desirable that cancer biologists will use this data to develop
and test hypotheses, realistically, few wet-laboratory researchers have the infrastructure or knowledge regarding
scores of complex bioinformatics tools to glean a higher
understanding from the disparate sequence files and complex, scattered annotations. These challenges are leading
to the development of tools and secondary databases
which are expected to democratize Big Data use [8-10],
and initiatives such as the Human Variome Project has
started playing an important role by providing guidelines
that encourage standardizing and sharing of information
related to human genetic variation [11-13].
Biological information is usually concentrated in databases mainly of two types: primary databases comprised of
raw data submitted by researchers, and secondary databases that extract and filter the information available from
the primary databases and add additional annotations generated either manually or automatically through the efforts of biocurators [14-16]. One of the problems often
faced by end users of Big Data is the lack of curated information in primary NGS data repositories such as the
NCBI Short Read Archive (NCBI-SRA) [17] and The Cancer Genomics Hub (CGHub) [18]. It is expected that curated secondary databases will help organize the Big Data
and make it more user-friendly, similar to what secondary
database development efforts like RefSeq [19] and UniProtKB/Swiss-Prot [20] have done and are still doing for
GenBank [21]. Additional higher level databases like Pfam
[22], PIRSFs [23], KEGG [24] and others organize objects
into functional groups and provide information on biological function, networks and processes. It is clear that
knowledge can be gained when raw data moves in a vertical fashion, from millions of bases of DNA or RNA into
proteins, then to protein families, and finally into networks of interrelated biological processes. Currently, NGS
data in public repositories are not well connected to molecular biology resources and reference datasets, and
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validated methods for data processing and filtering are not
always available, necessitating significant bioinformatics
expertise to use and analyze such information. In this
paper, we describe a workflow to curate and analyze NGS
data from control (normal tissue) and case (tumor) samples derived from cancer patients. We chose to curate
publicly available NGS data to provide users an unbiased
view of variation that is present at the individual person
level and is not yet completely captured in dbSNP, thereby
providing a better understanding of the human variome.
Additionally, based on our previous work on functional
analysis of non-synonymous Single Nucleotide Variations
(nsSNVs) from dbSNP [21], UniProt [20] and COSMIC
[25] we show how proteome-wide analysis of variation
can provide a detailed view of the distribution of variation
and possible functional impact [26-29].
Currently, there are thousands of large-scale sequence
data from cancer case and control samples that are available from primary short read data repositories such as
NCBI SRA and TCGA. It is expected that comprehensive
and integrated analysis of this data will lead to novel discoveries. We believe that computational and manual curation of this data will provide unprecedented value in
cancer research that will eventually lead to better cancer
detection, therapies, and care. As proof-of-concept, we
have analyzed nsSNVs from 55 samples (22 cases and 33
controls) obtained from 20 breast cancer patients and
have recorded the analysis results in Curated Short Read
(CSR) archive. The samples provide a rich source of sequence data that can be mined to extend and compliment
mutation and single-nucleotide polymorphism (SNP) information available from dbSNP [21], UniProt [20], COSMIC [25] and other variation databases. We intend to
curate and analyze representative samples from all datasets that are available through TCGA. For our initial study,
through focused analysis of the breast cancer samples, we
show how a workflow that identifies novel variations, explores the effects of nsSNVs on the human proteome and
classification of patients based on Single Nucleotide Variations (SNVs) can provide a higher level of information that
can be used by researchers to evaluate experimental targets and also to generate and test hypothesis related to
personalized medicine. To facilitate implementation of
this workflow by other users, we provide nsSNV analysis
tool - SNVDis that can be used by researchers or biocurators interested in evaluating the effects of variation. With
large-scale informatics fast becoming an integral component of cancer research, the workflow described here can
be easily applied to other datasets.

Methods
Architecture and computational environment

All data displayed on the website as well as any data or
references used in the analysis are stored in the High-
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performance Integrated Virtual Environment (HIVE)
server (http://hive.biochemistry.gwu.edu) [30]. The results are searchable and are also available as tabdelimited files. Users can either browse the curated data
or search for specific genes or proteins using RefSeq accession number as the query. Searches with TCGA IDs
and UniProtKB accession numbers are also supported.
HIVE provides the storage and analysis computational
infrastructure for this project. Resources include six Dell
Servers, an integrated computational environment, and
10GB 48port Ethernet switch and control servers. The
workflow is also incorporated within the CloudBioLinux
[31] environment (Figure 1). Cloud BioLinux VM can be
downloaded from https://s3.amazonaws.com/cloudbio
linuxvms/cloudbiolinuxsra/cloudbiolinuxsra.ova. Installation instructions are available at http://www.cloudbio
linux.org and http://www.virtualbox.org/manual/ch01.
html#ovf.
Datasets

Short read data is obtained from The Cancer Genome
Atlas (http://cancergenome.nih.gov/) via the CGHub
data portal (https://cghub.ucsc.edu/). The reference used
in the alignment is the hg19,
GRCh37 Genome Reference Consortium Human
Reference 37 (GCA_000001405.1) downloaded from
UCSC (http://hgdownload.cse.ucsc.edu/goldenPath/hg19/
chromosomes/). UniProtKB protein amino acid position
and ID mapping is done using SNVDis and ID Mapping
services [28,32]. Functional and sequence information is
obtained from RefSeq [19], Conserved Domain Database
[33], UniProtKB/Swiss-Prot [20] and CCDS [34].
Data selection criteria

For this study, we concentrate on sequence data from
breast cancer cases and controls. Data sets derived from
twenty patients are selected for analysis. The criterion
for selection is based on the availability of clinical information, race, paired case and control samples. In addition
to this, the presence of both exome and RNA-Seq data
from the same patient is also included as a criterion for selection because they are deemed to be high-priority datasets by our users because many hypothesis driven
questions can be answered through the comparative analysis of these datasets. Information is retrieved using the
data matrix available at https://tcga-data.nci.nih.gov/tcga/
dataAccessMatrix.htm. “BRCA-Breast invasive carcinoma”
is selected as “Disease type” and “Clinical” from the “Data
Type”. Patients from three different races are included:
three patients from African-American, one Asian, and the
rest White. All patients are females and had no previous
history of malignancy. The tumor and the matched control samples can be identified by the TCGA barcode associated with each sample. A TCGA barcode is a collection
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of identifiers such as in the sample ID (TCGA-CH-573901A-11D-1576-08), where 5739 is the participant number,
01 is the sample type. Tumor sample range from 01–09
and matched normal from 10 – 19 depending on the type
of tumor and normal sample. The short reads are then
mapped to the human reference sequence and further analyzed to identify variations.
SNV filtration and annotation

After the raw SNV data is generated using Bowtie [35]
and SAMtools [36], filters are used to select high quality
SNVs which are of desirable coverage (>10 reads) and
quality score (>20). The filtration process also rejects detected SNVs falling out of the exome regions, which may
be caused by non-unique regions in the genome.
nsSNV distribution on functional sites

Experimental Post Translational Modification (PTM) sites
are obtained from UniProtKB/Swiss-Prot [20] and dbPTM
3.0 [37], which provides experimentally verified PTM sites.
Python scripts are used to remove the redundancy from
the nsSNVs dataset, map the resulting unique nsSNVs to
PTM motifs in UniProtKB proteins, and calculate how
many PTM sites are detected to have nsSNV. Any nsSNV
derived unacceptable change on the given PTM motif is
considered as a loss of PTM site. To evaluate the effects
of nsSNVs obtained from case and control samples, statistics were generated and heatmap was constructed using R
package [38]. To obtain the heatmap, the binary matrix
data of presence or absence of SNV in a particular position is loaded into R and using the packages ggplot2 and
reshape, the binary heatmap is obtained by converting the
values of each cell into either red ‘present in only case or
control’ or green ‘present in both case and control’. This
information is then plotted with the amino acid positions
across the vertical axis.
Tools

The CGquery and Gene Torrent utilities (https://cghub.
ucsc.edu/software/downloads.html) are used to search
for and retrieve BAM files from CGHub. Alignment is
performed using Bowtie version 0.12.5 [35]. SNVs are
calculated using SAMtools version 0.1.18 and bcftools
version 0.1.17 [36]. The pipeline consists of a series of
Perl scripts and the above-mentioned software which are
called using a wrapper script. The wrapper is accessed
via the command line and accepts two arguments, a list
of fastq files that needs to be analyzed and the location
where the output should be placed. The statistics are
generated with R [38].
Phylogenetic analysis and SNV visualization

A novel algorithm (phyloSNP) has been developed to create
SNV-based phylogentic trees. The first step involves creating
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Figure 1 Cloud BioLinux environment. A) Computational infrastructure; B) Cloud BioLinux SRA provides a command line interface for mapping
and SNV identification and Oracle VM VirtualBox manager allows user to edit settings C) Appliance Import Wizard allows import of appliance in
Open Virtualization format. D) Snapshot of applications available through Cloud BioLinux environment.

an alignment that contains genomic sequence around SNVs.
For this study we chose to include zero, one and two nucleotides upstream and downstream of every SNV to create

SNV-shrunk genome. More specifically, the SNV-shrunk
genome alignments are created using phyloSNP (https://
hive.biochemistry.gwu.edu/hive/dna.cgi?cmd=phylosnp)
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by concatenating regions of the genome that has SNV for
each sample. If one sample has a SNV in a particular position then all of the other SNV-shrunk genomes from the
other samples include that region in their SNV-shrunk
genome. Therefore the output of all SNV-shrunk genomes
is an alignment. This alignment is then used to generate
neighbor joining phylogenetic trees using Clustal with 100
bootstrap values [39]. Bootstrap values indicate the confidence of the branches in the estimated trees. The trees are
viewed in TreeView [40].
Functional analysis

Filtered SNVs are submitted to Seattleseq 137 Annotation Service [41] to get positional and functional annotation. Additional functional analysis of proteins affected
by nsSNVs is performed based on methods described
earlier [26-28]. Briefly, nsSNV data is uploaded into
SNVDis database and integrated with protein sequence
features obtained from UniProtKB/Swiss-Prot [20], Conserved Domain Database (CDD) and RefSeq of NCBI
[42]. SNVDis provides graphical and tabular output of
variations that affect functionally annotated sequence
sites. Additionally, SNVDis also provides information if
there is an over- or under-representation of certain pathways and domains that are affected by nsSNVs. Gene
Ontology analysis of genes affected by rare variants is
performed using PANTHER tools [43,44].

Page 5 of 18

project [29]. The effects that a specific variation has on a
protein function have been the focus of studies for quite
some time with several tools that predict SNV effects
[54-57]. Proteome-wide analysis of variation that affects
known functional sites [26-28,58] is another way of estimating how variation can affect function at a system
level and if there are specific domains or pathways that
are more prone to having variations.
In this study, we analyze patient derived samples to
identify nsSNVs that are in concordance with dbSNP and
also novel variations, determine the effect of nsSNVs on
the proteome and classify the patients based on phylogentic analysis of the nsSNVs. Figure 2 provides a flowchart
of the workflow that involves retrieving sequence data
from TCGA followed by mapping the short sequence
reads to human reference genome and identification of
SNVs. Subsequently, SNVs are mapped to protein sequences and the proteome-wide distribution of SNV is investigated. All of the nsSNV data and sample-specific
annotations are then recorded and is made available at the
Curated Short-Read database (CSR). Users studying specific cancer genes or proteins or the entire patient proteome can query CSR in addition to known variation
databases such as dbSNP, COSMIC and UniProt to get a
comprehensive view of variation. Additionally, because all
of the data from this study, dbSNP, COSMIC and UniProt
are integrated into SNVDis, users can evaluate the effects
of all variations in addition to browsing them in CSR.

Key definitions

Case and control – Samples derived from paired tumor
(case) and normal (control) tissue; dbSNP overlap –
SNVs that are also found in dbSNP; novel SNV – found
only in the analyzed dataset; rare SNV – found in less
than 10% of the samples analyzed; common SNV –
found in 90% of the samples analyzed.

Results and discussion
SNVs are widely used to identify disease causing genes
and history of populations [45-47]. Many advances in
the diagnosis and treatment of cancers have been made
through such mutation discovery and analysis [48-52].
Combining the results of several studies (meta-analysis)
can increase the power of the analysis [53]. These metaanalyses combine the results (SNVs) from multiple studies and, using different statistical tools, identify the SNVs
most associated with a specific disease or phenotype.
Analysis of samples across different studies would provide a glimpse of the heterogeneity that is present in the
population and this information can then be used by researchers to connect genomic changes to diseases. Additionally, availability of variation data from control
samples can provide a more comprehensive understanding of the human variome in addition to what has been
determined by projects such as the 1000 Genomes

Metadata curation

There is a great need in biological research and discovery for curated metadata that is associated with short sequence reads. Just like GenBank, NCBI-SRA and other
public repository of short sequence reads around the
world are all primary databases with minimal or no curation. This means that it is extremely difficult for users
to search for and retrieve studies that can be used for
additional analysis or browse analysis results that are associated with specific genes of interest.
Sequencing has identified key disease specific mutations in many cancers where the authors filter variation
information from dbSNP to identify cancer specific variations [59]. The data in dbSNP does not yet capture all
possible individual level variation. Hence we intend to
focus on analyzing and curating samples which can be
used in conjunction with dbSNP data to better understand the human variome. For comparison purposes
both cases and controls are analyzed. The key fields that
we focus our curation efforts on are as follows: 1) Study,
experiment and sample title, type, abstract and associated
publications; 2) Organism name and taxonomy ID; 3)
Additional information wherever applicable such as sample type, tissue site, clinical status, age, gender, ethnicity
and gleason score; 4) Identification of nsSNVs; 5)

Cole et al. BMC Bioinformatics 2014, 15:28
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Figure 2 Short read sequence mapping and nsSNV analysis workflow. nsSNV variations are mapped to proteins to identify amino acid
changes. Functional site-specific information is extracted from UniProtKB, RefSeq and Conserved Domain Database.

Mapping of nsSNVs to dbSNP. In this project for tasks
one, two and three data is obtained from TCGA files and
manually verified. Publications that use TCGA data files
are searched for in PubMed [60] and manually checked to
confirm that they report analysis of cancer specific data
that is under consideration. For tasks four and five a computational approach that involves read mapping and SNV
calling followed by spot checks is performed. All metadata
data in CSR is manually verified and entered. Samples
which do not have the acceptable GC content of between
38-48% are not processed for curation.
The scientific name of the organism and the taxonomy
id are based on NCBI Taxonomy which are Homo sapiens
and 9606 respectively. The analysis presented here includes 55 samples from 20 patients where experiment
numbers CA00001BC - CA00022BC belong to cases and
CO00001BC - CO00033BC to controls. Case and control

samples start with a prefix CA and CO respectively,
followed by numbers and ends with a prefix for the cancer
type (Breast Cancer – BC). Each experiment accession
number is associated with a unique sample accession
number and belongs to same study. The experiment contains information regarding sequencing library strategy,
source, selection, layout and platform, which are obtained
from the metadata at CGhub. The CSR database provides
easy access to gene specific nsSNV variations found in
specific samples and also downloads of nsSNVs of case
and control samples with mappings to dbSNP which can
be used for additional analysis purposes. Table 1 provides
a snapshot of the information obtained when a protein or
gene accession number is used to search the CSR database. CSR data is also integrated into SNVDis for
proteome-wide analysis as described in the functional analysis section below.
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Table 1 Snapshot of information obtained upon searching the CSR database with a protein or gene accession number
RefSeq
nucleotide AC

Pos1

Chg2

Protein

Pos3

Chg

UniProt AC4

Pos5

NM_000059.3

1092

A|C

NP_000050.2

289

N|H

P51587

289

TCGA-BH-A0BW-01A-11D-A10Y-09 Breast Cancer Case

WXS6

NM_000059.3

1205

C|A

NP_000050.2

326

S|R

P51587

326

TCGA-BH-A0AZ-01A-21D-A12Q-09

Breast Cancer Case

WXS

NM_000059.3

1341

A|C

NP_000050.2

372

N|H

P51587

372

TCGA-AC-A2FF-01A-11D-A17D-09

Breast Cancer Case

WXS

Sample

Type

Library

1

Position in RefSeq nucleotide entry.
Nucleotide change.
Position in RefSeq protein entry.
4
UniProtKB/Swiss-Prot acceesion.
5
Position in UniProtKB/Swiss-Prot protein entry.
6
Whole exome sequencing.
2
3

Variation statistics

After the SNVs are called, filtering procedures as described in materials and methods are used to identify
high-quality SNVs. In order to investigate the distribution of the variants from 55 samples (some patients have
more than one control or case) derived from 20 patients,
we perform two types of comparison: 1) We compare
with dbSNP to calculate the proportion of known and
novel variants that we identify through our pipeline. 2)
Within this study comparison is conducted by calculating the common and rare SNVs and the concordance
(see descriptions of concordance, novel, common and
rare SNVs in Methods) between cases and control sets.
It is possible that sequencing errors can lead to identification of SNVs which in reality may not be present. Liu
et al. [61] performed a comprehensive study where they
showed that read preprocessing step did not improve the
accuracy of variant calling but ability to flag duplication,
local realignment and recalibration steps helped reduce
false positive and also sequencing depth was important.
The study also noticed SAMtools performed quite well
in identifying SNVs. Nonetheless, validation of the novel
nsSNVs identified through NGS analysis can be performed
using traditional Sanger sequencing of PCR products. For
example, novel variations found in this study if identified
in the NCI-60 exome samples for breast cancer cell lines
[62] can be easily validated using the procedure mentioned above. Further validation can also be performed
using peptide mass-spectrometry [63] for the nsSNVs.
Such validation will also become critical if any of the
novel nsSNVs that is identified through this study is
found in several samples and is hypothesized to be related
to the disease.
Overlap with dbSNP and analysis of novel variations

Regarding concordance with dbSNP, individual samples
show over 98% overlap with SNPs present in dbSNP version 137. In the total pool of the SNVs (all SNVs from
the study), over 92% and 94% of SNVs in cases and controls respectively are shared with dbSNP (Figure 3A).
The decrease in overlap percent when all the SNVs are
pooled compared to what is seen in individual samples

is due to overlap of dbSNP overlapping SNVs in multiple
samples with the novel SNVs remaining mostly unique.
More specifically, we find SNVs that are non-novel (also
found in dbSNP) in multiple samples while novel SNVs
found in individual samples are generally unique,
thereby increasing the ratio of unique SNVs when all
samples and cases are considered together (described in
greater detail in the next section). If SNVs that overlap
in both case and control are considered then the concordance with dbSNP increases to 96% as seen in the
last bar of the graph in Figure 3A. This moderate increase is most likely because the mutations that overlap
in case and control are most likely germline and are
inherited and expected to be found in general population and hence in dbSNP.
The total pool of SNVs is further grouped by their calculated frequency among samples in this study. The
SNVs with frequency higher than 10% are defined as
common SNVs while the SNVs lower than this frequency
are grouped into rare SNVs. The different percentage between novel and known (not present or present in dbSNP)
SNVs is illustrated in Figure 3B. As shown, in both cases
and control samples, the common SNVs are more likely
to have higher (almost 99%) overlap with dbSNP, while
rare SNVs, which are present in less than 10% of the
samples, have around 90% overlap with dbSNP. It is indeed possible that some of the novel mutations identified
can be cancer drivers as suggested in a recent paper by
Khurana et al. [29].
In order to explore the distribution preference of SNVs
of novel and known SNVs on genomic functional regions, all the SNVs were annotated using Seattleseq Annotation 137 web service [41]. Although not statistically
significant, from our dataset it appears that novel SNVs
are more prone to affect protein coding regions such as
missense, stop-gain, and splicing (Figure 3C).
Distribution of SNVs in cases and controls

In terms of overlap of SNVs in cases and controls- we
find that majority of the SNVs and nsSNVs overlap in
case and control samples with ~ 20% of such unique variations found in the nucleotide level and ~15% in amino

Cole et al. BMC Bioinformatics 2014, 15:28
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Figure 3 Known and novel SNVs classification based on comparison with dbSNP. A) The proportion of the novel/known SNVs in breast
cancer cases and control. The last bar indicates SNVs that overlap in case and control. B) Distribution of common and rare SNVs in dbSNP. As
expected SNVs that are rare (found in less than 10% of the samples analyzed) have a lower chance of being found in dbSNP. C) Functional
annotation of novel and known SNVs. For functional groups that have lower numbers a zoomed-in view is shown.

acids (Figure 4A). The correlation of SNVs between the
different data sets was further analyzed using phylogenetic analysis methods described later in this manuscript.
Comparing the number of SNVs that appear in one or
more of the samples shows that the largest percentage of

SNVs observed (33.34%) in the total pool of SNVs only
appear in frequency of 1.18% (one sample). This distribution shows the heterogeneity of the SNVs in the samples
and follows a trend similar to previous studies [29,64].
The graph (Figure 4B) presents a visual representation of

Cole et al. BMC Bioinformatics 2014, 15:28
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Control
Unique
68,019
23.67%

Overlap
219,349

Case
Unique
72,454
24.83%

Control
Unique
7,131
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Nucleotides

Overlap
37,862

Case
Unique
5,712
13.11%
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B
Number of SNVs
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Frequency in Total Samples (%)
Figure 4 SNV statistics. A) Numbers show the total nucleotides and amino acids affected by SNVs. B) Visual representation of the distribution of
SNVs in samples, showing that nearly 68% of all SNVs appear in 10% or lower frequency.

the data, showing that nearly 68% of all SNVs in the data
set appear in 10% or lower frequency of the total samples.
In terms of novel variations for individuals they range
from 1.27%-2.99% for control and 1.38%-4.00% for case.
There is only once case sample (A7-A0DB-A272) with
15.72% novel SNVs. Based on the clinical data it is not
clear why such a high number of SNVs are found in this
particular case. In TCGA this same patient has another
case sample where the numbers of novel SNVs are within
the range observed for other patients. The associated phylogentic analysis (details in next section) provides an easy
visualization and identification of samples that do not
have a normal distribution of SNVs and hence can be
followed up during the CSR curation process.
Functional analysis

The methodology adopted for functional analysis is based
on our earlier work [26,27]. In summary, we first evaluated the overall impact of the nsSNVs from the case and
control samples on the entire proteome (proteome-wide
analysis) in terms of effects on functional sites such as active sites, binding sites, co- and post-translational modification sites. Then we evaluate which domains and

pathways are most affected by variation. Additionally, we
also perform Gene Ontology, pathway and keyword analysis of the novel nsSNVs to better understand the effects
of variations which are presumably rare.
Proteome-wide analysis of the effects of nsSNVs

A broad analysis of all identified nsSNVs and also novel
nsSNVs (variations not found in dbSNP and other variation databases) was undertaken get a comprehensive
overview of the functional impact of variation. For this
analysis all the nsSNVs derived from the CSR project are
integrated into a proteome-wide analysis CSR companion
tool SNVDis [28]. SNVDis is integrated into a High Performance Integrated Virtual Environment (HIVE) [30]
that allows proteome-wide analysis of the nsSNVs. The
SNVDis tool home page shows nine sources of variation
data with two of them coming from this study (TCGABreast-Control and TCGA-Breast-Case). The default
proteome that the analysis is performed on is UniProtKB/
Swiss-Prot defined human proteome. In the analysis box
in SNVDis one can choose what type of analysis they wish
to perform. For example, selecting TCGA-Breast-Control
and TCGA-Breast-Case and binding site will retrieve all
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nsSNVs that alter protein binding sites (as defined by UniProtKB/Swiss-Prot [20] and CDD [33] curators). This tool
provides a comprehensive overview of how the nsSNVs affects active sites, binding sites, N-linked glycosylation
sites, protein domains and pathways. For example, selecting the active sites (includes site annotations from both
UniProt and CDD) that are affected by nsSNVs from the
breast cancer case and control samples retrieves 56 sites
in 44 proteins.
For pathway and domain analysis SNVDis estimates the
number of expected variations to find in the domain or
pathway based on uniform distribution of nsSNVs. For
pathway analysis the UniProtKB/Swiss-Prot is selected
and from the ‘Select dataset’ box TCGA-Breast-Control
and TCGA-Breast-Cancer is selected and from the
‘nsSNV analysis on’ box ‘Pathways’ tab is selected followed
by selected of the ‘by significance’ option. A p-value cutoff
of 0.0000001 is chosen. The top five pathways that are affected when both cases and controls are taken together
are Nicotine degradation (observed: 81, expected: 33.2,
p value: 1.11E-16), FAS signaling pathway (observed: 81,
expected: 33.2, p value: 1.11E-16), DPP-SCW signaling
pathway (observed: 76, expected: 37.9, p value: 5.83E-10),
Cadherin signaling pathway (observed: 433, expected:
280.0, p value: 3.93e-20) and Blood coagulation (observed:
156, expected: 87.2, p value: 1.69e-13). No immediate
correlation to cancer pathways can be drawn from this
analysis other than the fact that changes to signaling
pathways are considered to be important in cancer progression [65].
Using a similar protocol as described above the top
five functional domains (sorted based on p-value) that
are affected in case and control samples are found to
be almost identical: the transmembrane olfactory receptor (Pfam ID: PF13853), the cysteine rich domain
that occurs alongside the TIL domain (PF12714), the
glycoprotein-fucosylgalactoside a-N-acetylgalactosaminyltransferase domain (PF03414), a mammalian taste receptor protein domain (PF05296) and a protein kinase
domain (PF00069) for the case sample and for the control
samples instead of the kinase domain the glycoside hydrolase family 18 domain (PF00704) has over-representation
of nsSNVs. Interestingly the greatest difference observed
between control and sample analysis was the fact that the
hyaluronan/mRNA binding domain (PF04774) is significantly affected more in the case samples (observed: 17; expected: 3.6; p value 1.26E-12) than the control samples
(observed: 9; expected: 3; p value 6.41E-03). Increased
levels of hyalunonan have already been correlated to
breast cancer and often are used as a marker [66]. More
samples would need to be analyzed to confirm this
correlation.
As described earlier the number of case only or control only nsSNVs are less than 20% of the total variations
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and analyzing for over- or under-representation for cases
and controls separately did not result in any appreciable
differences in the highly affected pathways and domains.
Therefore, a more detailed analysis of just the novel
nsSNVs and their effects on functional sites was undertaken, results of which are described in the next section.
Enrichment analysis of novel nsSNV affected proteins

In addition to the proteome-wide analysis of all nsSNVs
an analysis of genes that are impacted by novel nsSNVs
was also performed. For this analysis from case samples
a total 17,177 novel nsSNVs containing gene accession
numbers are mapped to 8,896 UniProtKB/Swiss-prot
proteins and for novel nsSNVs in controls 13,523 gene
identifiers are mapped to 6,961 UniProtKB/Swiss-Prot
proteins. A decrease in the number of proteins compared to the number of initial RefSeq gene identifiers is
because UniProtKB/Swiss-Prot entries represent the canonical protein whereas the genes in RefSeq can represent different isoforms. An initial analysis using the
UniProtKB/Swiss-Prot keyword ‘Disease’ shows that the
keyword is over-represented in the gene list having novel
nsSNVs from case (observed: 1524; expected: 1211; p-value:
5.22E-21). Novel nsSNVs in the controls also appear to
be over-represented albeit with a less significant p-value
(observed: 1155; expected: 948; p-value: 6.46E-09). Based
on UniProtKB/Swiss-Prot protein entry annotations of
genes that are considered oncogenes, proto-oncogenes
and tumor suppressors; for novel nsSNVs that are only
found in case samples there seems to be a slight overrepresentation of tumor suppressor genes (observed: 43;
expected: 27; p-value: 3.84E-03). It is important to note
that cancer disease annotations in UniProtKB/Swiss-Prot
(or in any other database) are far from being comprehensive. As more patient samples are analyzed and the disease
specific annotations improve it will be possible to identify
through this type of analysis if specific genes that are involved in cancer do indeed have higher level of mutations
both in the controls and cases.
Additional functional analysis of genes which novel
nsSNVs was performed to investigate if specific pathways,
protein families or Gene Ontology (GO) terms are overor under-represented. Pathway analysis shows that several
of the top pathways (Table 2) are known to be involved in
cancer. Other notable pathways known to be involved in
cancer with less significant p-values include Wnt signaling
pathway (observed: 205; expected: 161.67; p-value: 9.29E02), Angiogenesis (observed: 119; expected: 87.71; p-value:
1.44E-01) and EGF receptor signaling pathway (observed:
86; expected: 64; p-value: 8.65E-01).
Over- and under-representation of Gene Ontology (GO)
terms, PANTHER pathways and protein classification in
the list of genes which have novel nsSNVs provides an
overview of what broad effects these novel variations
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Table 2 Functional analysis of novel nsSNV containing genes
Analysis

Functional object

Observed

Expected

+/−

P value

PANTHER pathways

Integrin signaling pathway

147

99.09

+

6.43E-04

Cadherin signaling pathway

109

74.91

+

2.15E-02

Endothelin signaling pathway

62

38.88

+

6.55E-02

Gonadotropin releasing hormone receptor pathway

174

133.70

+

7.71E-02

Nicotinic acetylcholine receptor signaling pathway

75

49.78

+

8.78E-02

Cell adhesion molecule

443

316.70

+

9.28E-10

G-protein modulator

346

238.47

+

3.82E-09

enzyme modulator

906

730.11

+

5.69E-09

kinase

431

312.91

+

1.28E-08

PANTHER protein classification

GO biological process

GO molecular function

GO cellular component

cytoskeletal protein

585

452.77

+

1.02E-07

Cell communication

2333

2002.60

+

3.16E-14

Cell adhesion

820

616.80

+

6.15E-14

Signal transduction

2204

1905.41

+

5.32E-12

Cellular component organization

773

595.00

+

4.72E-11

Protein modification process

804

630.55

+

5.80E-10

Hydrolase activity

1295

1053.92

+

1.81E-12

Transferase activity

962

759.03

+

1.12E-11

Protein binding

1715

1456.91

+

5.40E-11

Transmembrane transporter activity

609

460.35

+

9.79E-10

Enzyme regulator activity

732

576.51

+

1.05E-08

Cytoskeleton

585

452.77

+

2.03E-08

Intracellular

681

540.47

+

3.98E-08

Actin cytoskeleton

302

229.94

+

8.66E-05

MHC protein complex

18

40.30

-

2.37E-03

Extracellular matrix

327

264.55

+

3.33E-03

might have. The major terms for Gene Ontology (GO)
Biological Processes that are highly over-represented (pvalue >1E-24) are metabolic process, cellular process and
transport (primarily protein and ion transport). Table 2
provides a breakdown of the major terms. For GO Molecular Function the major terms include catalytic activity,
binding (includes protein binding) and transporter activity
(p-value >1E-9). Other notable GO Molecular Function
includes kinase activity (observed: 432; expected: 314.80;
p-value: 1.60E-08) and ion channel activity (observed: 242;
expected: 186.80; p-value: 7.75E-03). Many of the pathways identified as over-represented in the gene list are associated with cancer [67,68]. For example, it is known that
integrins and cadherins initiate signaling pathways that
control the activity of Rho family GTPases [69]. Other
terms that are over-represented are related to cell adhesion, cell communication, and signal transduction all of
which are associated proteins that play active roles during
tissue development and tumour metastasis [69]. Additional over-represented GO terms such as protein modification (e.g. post-translational modification (PTM) and

enzymatic activity was further investigated to see if any of
the mutations were resulting in loss of function PTM
motif or active or binding sites of proteins.
Functional analysis of proteins with variations in functional sites. A more comprehensive analysis of the effects
of nsSNVs is undertaken to better understand how they
affect the functional sites. For this analysis all nsSNVs
from case and control samples are mapped to UniProtKB PTM sequence features and dbPTM entries to
analyze the distribution of nsSNVs on PTM sites. The
database dbPTM is a non-redundant collection of experimentally verified PTM sites extracted from various
related databases and publications [37]. dbPTM currently consists of 18 different types of PTMs from related databases and publications. Out of approximately
30,000 nsSNVs identified in case samples and similar
numbers from controls the following functional sites
were found to be affected: O-linked Glycosylation (case:
4; control: 4), Methylation (case: 3; control: 1), Acetylation (case: 8; control: 6), N-linked Glycosylation (case:
56; control: 64), Phosphorylation (case: 110; control:
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108), Ubiquitylation (case: 15; control: 17), Binding Site
(case: 2; control: 3), Active Site (case: 4; control: 2). Protein accession numbers and amino acid position for this
data is provided in Additional file 1: Table S1 and graphically represented in Figure 5A and 5B. A search in UniProtKB/Swiss-Prot shows that several of these proteins
that are affected by variation are implicated in cancer
based on annotation in the Comments section of the entry
(CC lines) [20]. Examples include, calcium-activated
chloride channel regulator 2 (CLCA2), which is considered to act as a tumor suppressor in breast cancer [70];
ADAMTS-like protein 3 (ADAMTSL3) is expressed by
malignant epithelial cells in colon cancer, as well as breast,
prostate, renal and skin tumors [71]; clusterin is an antiapoptotic protein associated with breast, prostate and
other cancer types [72]; aberrant expression of macrophage colony-stimulating factor 1 (CSF1) can promote

A

1%

cancer cell proliferation, invasion and formation of metastases [73].
Based on our previous analysis results on the effects of
variation on active sites of proteins and N-linked glycosylation (NLG) sites [26,27,29] we here provide additional
details on these two important functional sites. Out of the
four proteins whose active site is disrupted (protein arginine N-methyltransferase 6 (PRMT6), chymase (CMA1),
kallikrein-5 (KLK5), sphingomyelin phosphodiesterase 3
(SMPD3)) two of the proteins have them disrupted in
both cases and controls. PRMT6 active site variation is detected in 3 samples (one case and two controls from one
patient (TCGA-BH-A0DK); CMA1 variation is detected in
two case samples from same patient (TCGA-A7-A0DB01A-11D-A272-09,TCGA-A7-A0DB-01C-02D-A272-09);
KLK5 exists in 75% of the samples (16 case samples and
25 control samples); SMPD3 exists in only one patient

2% 2% 2%

7%

C

4%

O-linked Glycosylation

Overlapping nsSNVs
Non-overlapping nsSNVs

Methylation

N-linked Glycosylation
Phosphorylation
Ubiquitylation
Binding Site

54%

Active Site

B

1% 1% 2% 1% 3%
8%

O-linked Glycosylation
Methylation
Acetylation
31%

N-linked Glycosylation
Phosphorylation
Ubiquitylation

53%

IDs based on protein position coordinates

Acetylation
28%

Binding Site
Active Site

Figure 5 Distribution of functional sites from UniProtKB/Swiss-Prot that affected by nsSNVs. A) Distribution of loss of functional sites
caused by nsSNVs from cases. B) Distribution of loss of functional sites caused by nsSNVs from controls. C) Heatmap representation of the
overlap of nsSNVs in cases and control (nsSNVs found in both cases and controls are marked green and marked red if they are unique to case or
control. All protein accessions and corresponding position were given a numerical ID (Additional file 1: Table S1) to facilitate visualization of the
vertical axis in the heatmap.
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sample (TCGA-A7-A0DB-01C-02D-A272-09). KLK5 and
its trypsin-like serine protease paralogs have been associated with several cancers [74]. KLK5 active site variation
which possibly deactivates the enzyme in a high percent of
samples (both cases and controls) is most likely possible
because one of the other paralogs (there are 15 members
in the Kallikrein subfamily according to UniProtKB/SwissProt) might have the ability to compensate for the loss of
activity of one its members. For CMA1and SMPD3, the
active site disruptions are found only in cases. Chymases
are known to convert angiotensin I to angiotensin II, and
influences of angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks has been proposed before [75,76]. Finding this mutation in breast cancer tumor
provides a novel target for further investigation on the role
of this gene in breast cancer. Similarly, SMPD3 is known
to catalyze the hydrolysis of sphingomyelin to form ceramide and phosphocholine and ceramide mediates cellular
functions, such as apoptosis and growth arrest [20,77].
Mutations in SMPD3 have implicated the ceramide pathway in human leukemias [78]. Identification of loss of
function mutation of SMPD3 due to a mutation in the
active site of the enzyme in breast cancer tumor cells
provides for the first time a potential association of this
gene with breast cancer.
The asparagine-X-serine/threonine (NXS/T) motif,
where X is any amino acid except proline, is the consensus motif for NLG. Therefore, mutations in this motif
can lead to loss of NLG. Previously, we have shown
through proteome-wide analysis how germline mutations can result in loss-of-glycosylation (LOG) [27]. In
analyzing the somatic mutations of breast cancer patients we find 56 such LOG mutations in cases and 64
LOGs in controls (Additional file 1: Table S1). Out of
these LOG sites 5 are unique to case samples (P08F94,
Fibrocystin/PKHD1, position 830; P15151, Poliovirus receptor/PVR, position 122; P40126, L-dopachrome tautomerase/DCT, position 170; P52797, Ephrin-A3/EFNA3,
position 102; P58170, Olfactory receptor 1D5/OR1D5,
position 7; Q9NYQ6, Cadherin EGF LAG seven-pass Gtype receptor 1/CELSR1, position 1289. All of these mutations appear to be novel except for Fibrocystin N- > S
mutation at position 830 which amongst other mutations has been implicated in polycystic kidney disease
[79,80] but not cancer.
Phylogenetic analysis

It is our hypothesis that phylogenetic analysis of SNVs can
provide a better way of characterizing control and case
samples. SNV based characterization methods have been
used before [81,82] but currently there are no phylogenetic analysis tools that allow for direct generation of trees
from human SNVs identified in a next-generation sequence analysis pipeline. As described in Materials and
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Methods we have developed phyloSNP, which allows generation of SNV-shrunk genome alignments which can be
used to create phylogenetic trees using existing tree building software such as MEGA [83], Clustal [39] etc.
Race and ethnicity information associated with patient
samples may not always be the optimal method to
categorize and evaluate genomic data [84]. Each sample
is assigned an ID corresponding to the second and third
TCGA call numbers along with a control or case tag.
From here, all 55 samples are analyzed using phyloSNP
shrunk-genomes with a delta 0 (only positions with the
SNV was extracted and concatenated to create the SNVshrunk genome). Increasing the delta to 10 did not significantly improve the tree (data not shown). A phylogenetic tree from the resulting genomic sequences was
generated using ClustalW2 with 100 bootstrap replicates
(Figure 6). All the cases and controls from the same patient branch together. For one patient (A7-A0DB) there
are 6 samples (three cases and three controls). One case
groups with two other controls from the same patient
and the other two cases groups with another control
from the same patient. It is interesting to note that although the numbers of novel SNVs are within 1.38%4.00% for the sample A7-A0DB-A272 case2 there is
15.72% novel SNVs. For case1 from this patient the
number of nsSNVs is within the accepted range. There
is no information in the TCGA patient annotation files
which provides any additional information as to why
there is such high number of variations in this particular
case. More samples need to be analyzed before any specific classification related correlations with disease or
therapy can be made. It is evident even from the small
sample size that SNV profiles are not always correlated
with the ethnicity that was obtained from the sample annotations. It is our expectation that analysis of additional
samples would allow us to create discrete bins which can
then be used to categorize the samples, identify outgroups
and even evaluate the quality of the sequence data. Such
classification can be of great use for biomarker discovery
processes if they can be correlated with disease outcome
or other phenotypic characteristics. For 20 patient samples
we did not find any correlation with the two major
branches that can be seen in Figure 6 and clinical annotations available in the TCGA data files. It is important to
note that the amount of clinical information available in
the TCGA data files is limited and it is possible that with
the availability of additional clinical or phenotypic data or
through the analysis of data from additional patients we
will be able to correlate classification results with specific
clinical or phenotypic information.
Web interface and usage

The CSR metadata home page (http://hive.biochemistry.gwu.
edu/dna.cgi?cmd=csr) contains all available data related to
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Figure 6 Phylogenetic analysis of patient samples based on SNVs. SNV-shrunk genome alignment comprising nucleotides from just the variation
position is used (delta 0). Colored branches represent the ethnicity of the person from which the sample was taken with blue representing White,
orange representing Asian, and red representing African-American. Bootstrap values of 75 and higher are shown. Two major groups are noticed
with 98 and 78 bootstrap values.

this study. RefSeq gene and protein accession numbers can
be used to retrieve results for single genes and SNV downloads are also available from the website. Variation results for
single proteins are integrated with variation data from
dbSNP, COSMIC and UniProt to easily identify variations
that are sample specific and if they overlap with any known
variations. Additionally, there are links from the sample
pages to CBio cancer genomics portal [85] which provides
additional information on the TCGA samples. Annotation
data from TCGA data portal files are manually checked and
combined with computationally analyzed mapping and SNV
data and entered into CSR database. Clicking on the
‘Reviewed short read data’ brings the user to the ‘Curated
SRA Browsing Interface’ which contains headers linked to
‘study’, ‘experiment’ and ‘sample’. Clicking on each of these
links takes the user to the respective curated datasets which
can be browsed. The study, experiment and samples are
hierarchical. Whenever possible, identifiers are inherited
from the primary database (in this case TCGA) to ensure

easy tracking of data. For the experiments new identifiers
were created to indicate if the samples are cases on control.
The described approach can be used by others by to
analyze and document variations from other individuals
available from TCGA and many other datasets available via
dbGaP [82] thereby providing a better view of the human
variome. It is expected that this type of bioinformatic analysis in conjunction with phenotypic information will allow
researchers to correlate variation information with functional changes. Additional immediate impact of the CSR
database will be providing access to variation data from individuals about specific genes. For example, a user studying
the NM_001099771.2 gene (UniProt accession A5A3E0;
POTE ankyrin domain family member F) might be interested in knowing what variations are present in this gene. A
survey of variations for this gene in dbSNP shows that there
are 186 known SNPs. From our analysis we find an additional 22 SNVs out of which there is one nsSNV which results in the loss of a phosphorylation site (amino acid
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position 918 Y|F mutation). The protein is known to be
expressed in breast cancer cell lines [86]. In studies such as
these if a rare nsSNV is observed in a critical functional site
one would most likely try to estimate its impact through
additional experimentation. An example of such follow up
study where the variation impacts an active site of an enzyme could be assaying for buildup of substrate or decrease
in the level of product [26]. If the nsSNV affects a PTM site
[27] such as N-linked glycosylation then one would need to
perform possibly additional analytical studies to evaluate the
impact [87]. System level impact of nsSNVs and additional
network analysis can also be applied to such analysis to better understand the personal genome [88-90]. For additional
proteome-wide analysis of the impact of nsSNVs one can
use SNVDis [28] as described in earlier sections.
CloudBioLinux

CloudBiolinux [31] (http://www.cloudbiolinux.org), is a
bioinformatics Virtual Machine (VM) that is implemented to run on Amazon EC2, on the open-source,
private Cloud platform Eucalyptus (http://open.eucalyptus.com/), and on the desktop using VirtualBox (http://
www.virtualbox.org). A VM is a fully-featured UNIX server, in a format of a single, downloadable binary file that
executes on Clouds and desktop virtualization platforms.
Cloud BioLinux includes a full Ubuntu Linux (http://
www.ubuntu.com) and Galaxy Bioinformatics workbench
interface [91], while users can start the VMs with a few
clicks on the Amazon EC2 Cloud [92] without the need
for any advanced technical knowledge. The Cloud BioLinux VM includes a suite of bioinformatic programming libraries for R, Perl, Ruby, and Python in addition to more
than 100 pre-configured bioinformatics tools including
BLAST, Glimmer, HMMER, PHYLIP, RasMol, Genespring, Clustalw, and the EMBOSS analysis suite. Given
that the VM is accessible on the Amazon Cloud, it provides researchers with a large-scale, virtualized informatics
infrastructure without the financial or time burden of
owning and maintaining hardware and can therefore
democratize access to computational resources for smaller
laboratories which use NGS or other high throughput
genomics technologies for biological experiments.
We leveraged the software libraries and tools that are
available in the Cloud BioLinux VM, in order to install
and run our pipeline with minimal effort as most dependencies were already available inside the VM. Furthermore, the VM format allows us to distribute the
pipelines pre-configured and ready to execute in a single
binary VM file that users can download and run on their
desktop computers. This allows other researchers in the
community to utilize our pipelines for their data analysis
needs, without being required to spend time performing
installations of bioinformatics tools or software libraries
to configure the dependencies of the pipeline. The VM
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is available for download at (https://s3.amazonaws.com/
cloudbiolinuxvms/cloudbiolinuxsra/cloudbiolinuxsra.ova)
and users can boot it on their desktop following the instructions on the VirtualBox website (http://www.virtualbox.org/manual/ch01.html#ovf ), while technical help is
available through the Cloud BioLinux user group forum
(https://groups.google.com/forum/?fromgroups#!forum/
cloudbiolinux).
This workflow takes an SRA file and a reference sequence and calculates the coverage and SNVs of the
reads when aligned against the reference sequence. The
program is run from the command line using Perl and
accepts as its parameters the base name and location of
the reference index file, the name and location of the
short read file; the name and location of the reference,
and the output directory. The output will include a file
containing putative SNPs, sequence coverage, and alignment statistics. The pipeline was run with a test input
dataset from the NCBI-SRA (SRR052047.sra) and sample
Bowtie2 indexes of the reference genome. The total runtime using a Cloud BioLinux Virtual Machine (VM, see
Methods for more details) that use one CPU core out of
four and two Gigabytes (GB) of memory on a laptop
computer was approximately fifteen minutes.

Conclusions
In this study we developed a workflow that involves
identification and analysis of nsSNVs and curation of the
metadata associated with TCGA samples. This information is available for browsing and downloads from CSR
database which we plan to continuously update with
representative datasets from all types of cancer with initial focus on curation of data from patients with both exome and RNA-sequencing data with matched cases and
controls. We consider these datasets important and currently there are 615 such patients with all the data and
sample types mentioned above. We plan to adhere to
the evolving Human Variome Project recommendations
and guidelines in terms of data formats and sharing. We
also provide a CloudBiolinux and proteome-wide analysis platform to allow users to analyze NGS data in their
research or biocuration pipelines. It is our belief that as
more datasets are curated by our group and others, we
will get a better understanding of the variability in human
populations. One limitation of adopting the workflow proposed here is the ability of individual researchers to have
the resources and expertise to perform next-generation sequence analysis. To overcome this limitation our group in
collaboration with US Food and Drug Administration has
been implementing the High-performance Integrated Virtual Environment (HIVE) which provides novel and known
sequence read mapping and variation calling algorithms in
a highly parallelized environment. It is our goal to provide
both enterprise level HIVE for institutions and HIVE-in-
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a-box for individual users thereby democratizing the ability of scientists to work on Big Data.
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CSR: https://hive.biochemistry.gwu.edu/dna.cgi?cmd=csr
SNVDis: https://hive.biochemistry.gwu.edu/hive/snpdis.cgi?
cmd=dmSnpdis.
CloudBioLinux: https://s3.amazonaws.com/cloudbiolinuxvms/cloudbiolinuxsra/cloudbiolinuxsra.ova.
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